Diversion and Abuse of Buprenorphine

More documents

Recommendations

Info

Exhibit 19. Vermont TEDS Data – Treatment Admissions Related to Heroin or “Other Opiates” (including Buprenorphine) as the Primary Drug of Abuse, 1998 – 2004 12% 10% 8% 6% 4% 2% 0% Buprenorphine Assessment: Final Report 1998 1999 2000 2001 2002 2003 2004 Heroin Other Opiates Source: Substance Abuse and Mental Health Services Administration (Office of Applied Studies): Treatment Episode Data Set. To provide some context, the characteristics of Vermont patients who entered treatment with a primary problem with heroin and other opiates were analyzed, along with Medicaid data on buprenorphine clients in Exhibits 20, 21, and 22. Exhibit 20 shows that the percentages of TEDS clients in 2004 and buprenorphine Medicaid clients in 2005 who were female were similar. Exhibit 20. Vermont TEDS Data – Percent Female Treatment Admissions with Heroin, “Other Opiates” or Buprenorphine as the Primary Drug of Abuse: 1998 – 2005 60% 50% 40% 30% 20% 10% 0% 1998 1999 2000 2001 2002 2003 2004 2005 Sources: Vermont Medicaid data and Vermont Client Data System Heroin Other Opiates Buprenorphine Exhibits 21 and 22 show the age groups of Vermont patients for 1998-2004 as reported in TEDS, the age groups of Medicaid patients who received buprenorphine in 2005, and the average age of TEDS patients at the time of admission for problems with heroin or other opiates as reported in the Vermont treatment dataset. The buprenorphine patients were older than the TEDS heroin or other opiate patients. In 2004, 23 percent of the Vermont TEDS heroin patients and 35 percent of 42
the TEDS other opiate patients were over age 30, as compared to 39 percent of buprenorphine patients in 2005. Yet Vermont patients were young when compared to treatment admissions nationwide. For 2003 (the latest year for which data are available), 69 percent of the TEDS heroin patients across the U.S. and 58 percent of the other opiate patients were over age 30. 100 90 80 70 60 50 40 30 20 10 0 Buprenorphine Assessment: Final Report Exhibit 21. Vermont TEDS Heroin Treatment Admissions by Age Group: 1998-2004 and Buprenorphine Medicaid Clients: 2005 14 31 39 15 12 23 43 29 9 9 12 9 7 13 19 19 16 49 50 47 56 58 55 28 28 28 27 28 28 21 24 21 23 15 16 18 18 1998 1999 2000 2001 2002 2003 2004 2005 Bupe Source: SAMHSA Office of Applied Studies: Treatment Episode Data Set, and Vermont Medicaid Data and Vermont Client Data System 26 6 41-50 31-40 21-30 12--20 Av Age Exhibit 22. Vermont TEDS Other Opiate Admissions (including buprenorphine) by Age Group: 1998-2005 and Buprenorphine Medicaid Clients: 2005 100 90 80 70 60 50 40 30 20 10 0 26 42 24 6 19 35 32 33 20 32 18 30 33 36 33 32 11 10 13 16 14 14 13 24 24 46 37 42 55 31 30 29 30 20 17 19 20 26 1998 1999 2000 2001 2002 2003 2004 2005 6 Bupe Source: SAMHSA Office of Applied Studies: Treatment Episode Data Set, and Vermont Medicaid Data and Vermont Client Data System Although the Vermont patients were much younger than their counterparts elsewhere in the country, the patients in the other opiate category in Vermont were older than the patients being treated for heroin at the time they began using their primary drug of abuse (Exhibit 23). They also were older at the time of admission to treatment, were more likely to be employed full-time, 41-50 31-40 21-30 12--20 Av Age 43
Page 1: Diversion and Abuse of Buprenorphin
Page 5 and 6: Diversion and Abuse of Buprenorphin
Page 7 and 8: The actual review of the literature
Page 9 and 10: Risk Factors: The use of buprenorph
Page 11 and 12: prescribed dose to other persons wh
Page 13 and 14: In a separate report of data gather
Page 15 and 16: leading to heavy reliance on office
Page 17 and 18: 1. While adverse drug events associ
Page 19 and 20: At Columbia University, Herbert Kle
Page 21 and 22: Bridge TP, Fudala PJ, Herbert S et
Page 23 and 24: Gaul & Flaherty (2003b). Internet t
Page 25 and 26: Office of Applied Studies (2006a).
Page 27 and 28: APPENDIX A FEDERAL AND STATE OFFICI
Page 29 and 30: APPENDIX B INFORMATION SOURCES CONS
Page 31 and 32: APPENDIX C OUTSIDE EXPERTS CONSULTE
Page 33 and 34: TECHNICAL REPORT: ANALYSIS OF AVAIL
Page 35 and 36: Exhibit 3. Based on this estimate (
Page 37 and 38: Exhibit 5. DAWNLive! Continuously R
Page 39 and 40: 100% 90% 80% 70% 60% 50% 40% 30% 20
Page 41 and 42: Exhibit 12. DAWNLive! All Reporting
Page 43 and 44: increasing, especially cases involv
Page 45: See exhibits 37-44 for a full listi
Page 49 and 50: In the last two years, patients who
Page 51 and 52: self-medicating with buprenorphine.
Page 53 and 54: legally available in the U.S.) has
Page 55 and 56: engaging in activities such as rent
Page 57 and 58: Exhibit 33. Characteristics of Verm
Page 59 and 60: Exhibit 35. DAWN Live! ED Reports b
Page 61 and 62: 3000 2500 2000 1500 1000 500 0 Exhi
Page 63 and 64: 8000 7000 6000 5000 4000 3000 2000
Page 65 and 66: 400 350 300 250 200 150 100 50 0 A
Page 67 and 68: Exhibit 43. Oxycodone Items Analyze
Page 69 and 70: Exhibit 45. Total Number of Subutex

Diversion and Abuse of Buprenorphine

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?